Centrose

Centrose is pioneering a next-generation ADC platform centered on Extracellular Drug Conjugates (EDCs), which function entirely on the cell surface without internalization. This technology leverages the cell 'surfaceome'—specific networks of interacting proteins—to achieve high selectivity and potency while potentially reducing on-target, off-tumor toxicity. The company has a preclinical pipeline targeting metastatic cancers and lymphomas and has demonstrated proof-of-concept in non-human primate studies, positioning it to expand the targetable universe for antibody-conjugate therapies.

Extracellular Drug Conjugate (EDC) platform featuring non-internalizing, permanently linked antibody-drug conjugates that target specific protein networks (the surfaceome) on the cell exterior for selective cell killing.

Centrose competes in the crowded ADC space dominated by large pharma (e.g., AstraZeneca, Pfizer, Roche) and biotechs with next-gen ADC platforms (e.g., ImmunoGen, Seagen). Its key differentiation is the non-internalizing, dual-targeting EDC approach, which contrasts with most competitors focused on novel internalizing payloads, cleavable linkers, and bystander effects.